Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First in Human Safety and Ease of Use Assessment of 400mg Progesterone Callavid in Women With Luteal Phase Insufficiency

NCT07136922 is registered in ClinicalTrials.gov with Calla Lily Clinical Care Ltd as lead sponsor.

NCT NCT07136922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07136922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First in Human Safety and Ease of Use Assessment of 400mg Progesterone Callavid in Women With Luteal Phase Insufficiency
Lead sponsor
Calla Lily Clinical Care Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
April 20, 2026
Completion date
March 31, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

luteal phase insuffiency, progesterone delivery